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Background/Purpose
Differentiating patients who are infected or not in the
intensive care unit (ICU) can be very difficult. Present
diagnostic tests remain inadequate. CD64 has been
found to be a potentially useful marker to identify
infected patients. Unfortunately, CD64 measured by
standard flow cytometers in a laboratory takes hours to
perform. The purpose of this study was to evaluate the
Accellix CD64 instrument which provides results
in 20 minutes in ICU patients with and without
infections.
Method
Infected (ICUi) and non-infected ICU patients (ICU
Control-ICUc) and normal volunteers (C) had CD64
levels measured by the Accellix CD64 instrument. Mea-
surements were calculated as ‘CD64 index’, i.e. the ratio
between the fluorescence of the PMN population and
the fluorescence of control beads. ICU infection, ICU
control and normal control patients’ results can be seen
in Figure 1.
Results
Sixty patients were studied (ICUi-17, ICUc-13 and
C-30). CD64 Index levels were higher (mean ± SEM)
in ICU infection patients then ICU control and nor-
mal control patients (2.49 ± 0.42 vs. 1.28 ± 0.3 vs.
0.56 ± 0.02. p = 0.03 for ICUi vs. ICUc, p < 0.001 for
ICUi vs. C).
Conclusion
CD64 Index levels are higher in infected than non-
infected ICU patients. Accellix CD64 is a promising
instrument to differentiate infected from non-infected
ICU patients in a timely manner.
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